WCM
VKTX icon

Weld Capital Management’s Viking Therapeutics VKTX Stock Holding History

Weld Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-29,213
Closed -$211K – 672
2020
Q2 		$211K Sell
29,213
-7,097
-20% -$47.1K 0.08% 373
2020
Q1 		$170K Buy
+36,310
New +$223K 0.09% 333

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Weld Capital Management's VKTX Position: Q3 2020 in Review

Weld Capital Management sold out of Viking Therapeutics (VKTX) in Q3 2020, closing a stake of 29,213 shares — an estimated $211K sold.

Weld Capital Management first reported a position in VKTX in Q1 2020 and held it in 2 quarters. The position peaked at $211K in Q2 2020. 140 funds tracked by Wall St. Rank hold VKTX as of Q3 2020.

  • Weld Capital Management reported no remaining Viking Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Weld Capital Management sold 29,213 Viking Therapeutics shares in Q3 2020, an estimated $211K.
  • Weld Capital Management first reported a position in Viking Therapeutics in Q1 2020 and held it in 2 quarters.
  • Weld Capital Management's Viking Therapeutics position peaked at $211K in Q2 2020.
  • 140 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2020.

Based on Weld Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.